Glucox Biotech

Glucox Biotech is a preclinical-stage, private biotech firm pioneering the development of selective NOX4 inhibitors for metabolic and vascular diseases. The company's scientific foundation is built on targeting NADPH oxidase 4 (NOX4), an enzyme implicated in oxidative stress pathways driving diabetic complications, stroke, and kidney injury. Its lead candidate, GLX7013114, has been featured in peer-reviewed research for diabetic retinopathy, validating its approach. Glucox operates as a research-focused entity seeking academic and industry partnerships to advance its pipeline toward clinical development.

Discovery and development of highly selective small molecule inhibitors of NADPH oxidase 4 (NOX4), targeting oxidative stress pathways in chronic diseases.

The field of NOX inhibitors is emerging but competitive, with other biotech and academic groups exploring similar targets. Glucox's focus on selective NOX4 inhibition differentiates it from broader antioxidants. It faces potential competition from larger pharma companies with greater resources to enter the space.